经皮雌二醇联合运动在前列腺癌雄激素剥夺治疗中的研究(ESTRACISE):研究方案
ESTRACISE是一项开放标签IIA期随机对照试验方案,计划纳入310例接受外照射放疗联合辅助皮下雄激素剥夺治疗(ADT)的高危前列腺癌患者,按1:1随机分为经皮雌二醇(E2)凝胶+ADT组或单纯ADT对照组,另将120例患者随机纳入监督运动项目。主要终点为E2凝胶对扩展前列腺癌指数复合量表性功能领域评分恶化的缓解效果。
要点
- 经皮E2凝胶旨在减轻ADT对性功能等不良反应,主要终点为性功能领域评分。
- 310例高危前列腺癌患者按1:1随机分为E2+ADT组与单纯ADT组。
- 120例子集随机接受监督运动,评估E2联合运动的协同获益。
核心结论
- ESTRACISE研究的创新设计可提供经皮E2凝胶获益的新见解,亚研究可强化抗阻训练的获益并提供E2凝胶与运动协同获益的新见解,目前尚不清楚。
研究设计与样本
- 开放标签IIA期随机对照试验,计划纳入310例接受外照射放疗联合辅助皮下ADT的高危前列腺癌患者。
- 参与者按1:1随机分为E2+ADT组或单纯ADT对照组;另120例患者随机纳入监督运动项目。
- 方案已在euclinicaltrials.eu(2023-504704-28-00)和clinicaltrials.gov(NCT06271551)注册。
主要发现
- 主要终点依据E2缓解扩展前列腺癌指数复合量表性功能领域评分恶化的疗效评估。
- 次要终点包括ADT诱导不良反应的发生、E2的安全性与耐受性、E2联合或不联合运动对躯体、生理、肌肉及系统性生物标志物的影响以及生活质量。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To report the protocol of a study evaluating the efficacy of transdermal oestradiol (E2) gel in reducing the adverse effects of androgen deprivation therapy (ADT), specifically on sexual function, and to assess the utility of E2 in combination with supervised exercise. STUDY DESIGN AND METHODS: The primary endpoint of this open-label Phase IIA randomized controlled trial is the efficacy of transdermal E2 gel. Secondary endpoints include: (i) the occurrence of ADT-induced adverse effects; (ii) the safety and tolerability of E2; (iii) the impact of E2 with or without exercise on physical, physiological, muscle, and systemic biomarkers; and (iv) quality of life. The trial will recruit high-risk PCa patients (n = 310) undergoing external beam radiation therapy with adjuvant subcutaneous ADT. Participants will be stratified and randomized in a 1:1 ratio to either the E2 + ADT arm or the ADT-only control arm. Additionally, a subset of patients (n = 120) will be randomized into a supervised exercise programme. RESULTS: The primary outcome is assessed according to the efficacy of E2 in mitigating the deterioration of Expanded Prostate Cancer Index Composite sexual function domain scores. Secondary outcomes are assessed according to the occurrence of ADT-induced adverse effects, safety and tolerability of E2, impact of E2 with or without exercise on physical performance, body composition, bone mineral density, muscle size, systematic biomarkers, and quality of life. CONCLUSION: The ESTRACISE study's innovative design can offer novel insights about the benefits of E2 gel, and the substudy can reinforce the benefits resistance training and deliver valuable new novel insights into the synergistic benefits of E2 gel and exercise, which are currently unknown. TRIAL REGISTRATION: The protocol has been registered in euclinicaltrials.eu (2023-504704-28-00) and in clinicaltrials.gov (NCT06271551).
引用
- Jussila I, Ahtiainen JP, Laakkonen EK, et al. Transdermal oestradiol and exercise in androgen deprivation therapy (ESTRACISE): protocol. BJU Int. 2024. PMID: 38587276. doi:10.1111/bju.16361
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。